1186124-21-9

Basic information

• Product Name: 1-[({[5-(nitrooxy)hexyl]oxy}carbonyl)oxy]-1-methylethyl 2-ethoxy-1-{[2'-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate
• Synonyms: 1-[({[5-(nitrooxy)hexyl]oxy}carbonyl)oxy]-1-methylethyl 2-ethoxy-1-{[2'-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate
• CAS NO: 1186124-21-9
• Molecular Weight: 930.029
• Mol File: 1186124-21-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1-[({[5-(nitrooxy)hexyl]oxy}carbonyl)oxy]-1-methylethyl 2-ethoxy-1-{[2'-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[({[5-(nitrooxy)hexyl]oxy}carbonyl)oxy]-1-methylethyl 2-ethoxy-1-{[2'-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate(1186124-21-9)
• EPA Substance Registry System: 1-[({[5-(nitrooxy)hexyl]oxy}carbonyl)oxy]-1-methylethyl 2-ethoxy-1-{[2'-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate(1186124-21-9)

Safety Data

• Hazardous Substances Data: 1186124-21-9(Hazardous Substances Data)

Upstream product

• 1034454-30-2 1-methyl-1-{[(4-nitrophenoxy)carbonyl]oxy}ethyl 2-ethoxy-1-{[2'-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate 
• 1186124-19-5 5-(nitrooxy)hexanol 
• 1186124-20-8 5-(nitrooxy)hexyl 4-nitrobenzoate 
• 113493-16-6 C₁₃H₁₇NO₅ 
• 928-40-5 hexane-1,5-diol 
• 139481-72-4 2-Ethoxy-1-[[2'-(N-triphenylmethyltetrazol-5-yl)-biphenyl-4-yl]methyl]benzimidazole-7-carboxylic acid 

Downstream Products

• 1186123-59-0 1-[({[5-(nitrooxy)hexyl]oxy}carbonyl)oxy]-1-methylethyl 2-ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate 

Relevant articles and documents

ANGIOTENSIN II RECEPTOR ANTAGONISTS

The present invention relates to nitrooxyderivatives of angiotensin II receptor antagonist having the general formula (I): where in R is selected f rom the group consisting of (IIa) - (IIk): when R is selected from (Ilk), Y is selected from the group consisting of: 1) -C(O) (CH2) nR5; 2) -C(O)(CH2n-O-CH2-R5; 3) -C(O)-R6 wherein R6 is the following group: when R is selected from (IIa)-(IIh), Y is selected from the group consisting of: 4) -C(R1R2)OC(O)-(CH2)nR5; 5) -C(R1R2)OC(O)O-(CH2)nR5; 6) C(R1R2)OC(O)(CH2)n-O-CH2-R5; 7) C(R1R2)OC(O)O(CH2)n-O-CH2-R5; 8) -C(R1R2)OC(O)-R6 wherein R6 is as above defined; R1 and R2 are independently selected from the group consisting of hydrogen and C1-4 alkyl; R5 is -CH(ONO2)R7; R7 is CH3 or C1-4 alkyl; n is an integer from 1 to 4; or a pharmaceutically acceptable salt thereof.